摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-[4-(2-oxopropoxy)benzyl]-thiazolidine-2,4-dione | 153291-60-2

中文名称
——
中文别名
——
英文名称
5-[4-(2-oxopropoxy)benzyl]-thiazolidine-2,4-dione
英文别名
5-[4-(2-Oxopropoxy)benzyl]thiazolidine-2,4-dione;5-[[4-(2-oxopropoxy)phenyl]methyl]-1,3-thiazolidine-2,4-dione
5-[4-(2-oxopropoxy)benzyl]-thiazolidine-2,4-dione化学式
CAS
153291-60-2
化学式
C13H13NO4S
mdl
——
分子量
279.317
InChiKey
KYRUCCKXVHVIBR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    19
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    97.8
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-氨基-3-苯基丙烷-2-醇5-[4-(2-oxopropoxy)benzyl]-thiazolidine-2,4-dione甲醇氰基硼氢化钠 、 ice 、 氮气乙酸乙酯氯化钠Sodium sulfate-III乙醇 作用下, 以 为溶剂, 反应 18.5h, 以to give 590 mg of the title compound, melting at 145° C. to 152° C.的产率得到5-{4-[2-(3-Phenyl-2-hydroxypropylamino)propoxy]benzyl}thiazolidine-2,4-dione
    参考文献:
    名称:
    Thiazolidine and oxazolidine derivatives, their preparation and their
    摘要:
    式(I)的化合物:##STR1##及其盐、酯和溶剂和其前药,对于治疗和/或预防多种疾病有用,包括:高脂血症、高血糖、肥胖症、葡萄糖耐受不足、胰岛素抵抗和糖尿病并发症。
    公开号:
    US05578620A1
  • 作为产物:
    描述:
    ethyl 2-chloro-3-[4-(2-oxopropoxy)phenyl]propionate 、 硫脲环丁砜盐酸乙酸乙酯Sodium sulfate-III 、 silica gel 、 正己烷 作用下, 以 乙酸乙酯乙二醇甲醚 为溶剂, 反应 11.5h, 以to give 4.2 g of the title compound as crystals, melting at 158°-159° C.的产率得到5-[4-(2-oxopropoxy)benzyl]-thiazolidine-2,4-dione
    参考文献:
    名称:
    Oxazolidine derivatives having anti-diabetic and anti-obesity
    摘要:
    公式(I)的化合物:##STR1## 其中:R是烷基;X是氧或硫;Y是氢原子或--A--COOH,其中A是烷基;Ar是芳基或取代芳基基团;以及其药学上可接受的盐和酯,在糖尿病、肥胖症、高脂血症、高血糖、糖尿病并发症、肥胖相关高血压和骨质疏松症的治疗或预防中有用。
    公开号:
    US05436257A1
点击查看最新优质反应信息

文献信息

  • Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity
    申请人:Sankyo Company, Limited
    公开号:US05576340A1
    公开(公告)日:1996-11-19
    Compounds of formula (I): ##STR1## (wherein: R.sup.0 is hydrogen, methyl or hydroxymethyl; R.sup.1 is substituted alkyl; R.sup.2 and R.sup.3 are each hydrogen, halogen, hydroxy, alkoxy, carboxy, alkoxycarbonyl, alkyl, nitro, haloalkyl, or substituted alkyl; X is oxygen or sulfur; and Ar optionally substituted phenyl or naphthyl); and pharmaceutically acceptable salts thereof have a variety of valuable pharmaceutical activities, including anti-diabetic and anti-obesity activities; in addition, they are capable of treating or preventing hyperlipemia and hyperglycemia and, by inhibiting the action of aldose reductase, they can also be effective in the treatment and prevention of complications of diabetes.
    化合物的化学式(I):##STR1##(其中:R.sup.0为氢、甲基或羟甲基;R.sup.1为取代烷基;R.sup.2和R.sup.3分别为氢、卤素、羟基、烷氧基、羧基、烷氧羰基、烷基、硝基、卤代烷基或取代烷基;X为氧或硫;Ar为可选的取代苯基或萘基);以及其药学上可接受的盐具有多种有价值的药理活性,包括抗糖尿病和抗肥胖活性;此外,它们能够治疗或预防高脂血症和高血糖,并通过抑制醛糖还原酶的作用,它们还可以有效地治疗和预防糖尿病并发症。
  • Thiazolidine and oxazolidine derivatives, their preparation and their
    申请人:Sankyo Company, Limited
    公开号:US05578620A1
    公开(公告)日:1996-11-26
    Compounds of formula (I): ##STR1## and salts, esters and solyates thereof and pro-drugs therefor are useful for the treatment and/or prophylaxis of a variety of disorders, including one or more of: hyperlipemia, hyperglycemia, obesity, glucose tolerance insufficiency, insulin resistance and diabetic complications.
    公式(I)的化合物:##STR1##及其盐、酯和溶剂化合物以及其前体药物对于治疗和/或预防多种疾病非常有用,包括但不限于:高脂血症、高血糖、肥胖、葡萄糖耐量不足、胰岛素抵抗和糖尿病并发症。
  • THIAZOLIDINEDIONE ANALOGUES
    申请人:Colca Gerard R.
    公开号:US20130281414A1
    公开(公告)日:2013-10-24
    The present invention relates to thiazolidinedione analogues that are useful for treating liver afflictions such as nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
    本发明涉及噻唑烷二酮类似物,用于治疗肝脏疾病,如非酒精性脂肪肝病(NAFLD)或非酒精性脂肪性肝炎(NASH)。
  • Thiazolidinedione Analogues For The Treatment Of Hypertension
    申请人:Colca Gerard R.
    公开号:US20100222399A1
    公开(公告)日:2010-09-02
    The present invention relates to thiazolidinedione analogues that are useful for treating hypertension, diabetes, and inflammatory diseases. Formula (I), wherein: each of R 1 and R 4 is independently selected from H, halo, aliphatic, and alkoxy, wherein the aliphatic and alkoxy are optionally substituted with 1-3 of halo; R 2 is halo, hydroxy, or optionally substituted aliphatic, and R′ 2 is H, or R 2 and R′ 2 together form oxo; R 3 is H; and Ring A is a phenyl.
    本发明涉及用于治疗高血压、糖尿病和炎症性疾病的噻唑烷二酮类似物。公式(I),其中:R1和R4各自独立选择自H、卤素、脂肪基和烷氧基,其中所述脂肪基和烷氧基可以选择性地被1-3个卤素取代;R2为卤素、羟基或可选择性取代的脂肪基,而R′2为H,或R2和R′2共同形成氧代;R3为H;环A为苯基。
  • Process for Producing Thiazolidinedione Compound and Production Intermediate Thereof
    申请人:Nakamura Yoshitaka
    公开号:US20080103185A1
    公开(公告)日:2008-05-01
    There are provided crystals of a thiazolidinedione derivative having excellent prophylactic and therapeutic effects on a disease caused by insulin resistance and a process for producing the thiazolidinedione derivative with a high purity. As described above, a process for producing a compound represented by the general formula (A) or a salt thereof, comprising converting 4-[(2,4-dioxothiazolidin-5-yl)methyl]phenoxyacetic acid represented by the following formula into a compound of the general formula (I), wherein X=a halogen atom; then reacting the compound with a compound represented by the general formula (II), wherein R 1 , R 2 , R 3 and R 4 =a hydrogen atom, a hydroxyl group, C1-C6 alkyl, C1-C6 alkoxy, benzyloxy, acetoxy, trifluoromethyl or a halogen atom, R 5 =C1-C6 alkyl, and R 6 =a protecting group for an amino group, to produce a compound represented by the general formula (III); and subsequently cyclizing the compound into the final product, and crystals of a compound represented by the general formula (A) or a salt thereof.
    提供了一种噻唑烷二酮衍生物的晶体,具有对因胰岛素抵抗引起的疾病具有卓越的预防和治疗效果,并提供了一种高纯度制备噻唑烷二酮衍生物的方法。如上所述,提供了一种制备通式(A)化合物或其盐的方法,包括将以下式子所示的4-[(2,4-二氧噻唑烷-5-基)甲基]苯氧乙酸转化为通式(I)化合物,其中X为卤素原子; 然后将该化合物与通式(II)化合物反应,其中R1、R2、R3和R4为氢原子、羟基、C1-C6烷基、C1-C6烷氧基、苄氧基、乙酰氧基、三氟甲基或卤素原子,R5为C1-C6烷基,R6为氨基保护基,以制备通式(III)化合物; 然后将该化合物环化为最终产物,并提供了通式(A)化合物或其盐的晶体。
查看更多